Literature DB >> 26311612

Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp41 IgM antibodies.

Noushin Moshgabadi1, Rick A Galli2, Amelia C Daly2, Sze Mun Shirley Ko2, Tayla E Westgard2, Ashley F Bulpitt2, Christopher R Shackleton2.   

Abstract

BACKGROUND: Anti-HIV-1 IgM antibody is an important immunoassay target for early HIV antibody detection.
OBJECTIVES: The objective of this study is to determine if the early HIV antibody sensitivity of the 60s INSTI test is due to detection of anti-HIV-1 IgM in addition to IgG. STUDY
DESIGN: To demonstrate HIV gp41 IgM antibody capture by the INSTI HIV-1 gp41 recombinant antigen, an HIV-IgM ELISA was conducted with commercial HIV-1 seroconversion samples. To demonstrate that the INSTI dye-labelled Protein A-based colour developer (CD) has affinity to human IgM, commercial preparations of purified human immunoglobulins (IgM, IgD, IgA, IgE, and IgG) were blotted onto nitrocellulose (NC) and probed with the CD to observe spot development. To determine that INSTI is able to detect anti-HIV-1 IgM antibody, early seroconversion samples, were tested for reduced INSTI test spot intensity following IgM removal.
RESULTS: The gp41-based HIV-IgM ELISA results for 6 early seroconversion samples that were INSTI positive determined that the assay signal was due to anti-HIV-1 IgM antibody capture by the immobilised gp41 antigen. The dye-labelled Protein-A used in the INSTI CD produced distinct spots for purified IgM, IgA, and IgG blotted on the NC membrane. Following IgM removal from 21HIV-1 positive seroconversion samples with known or undetermined anti-HIV-1 IgM levels that were western blot negative or indeterminate, all samples had significantly reduced INSTI test spot intensity.
CONCLUSIONS: The INSTI HIV-1/HIV-2 Antibody Test is shown to detect anti-HIV-1 IgM antibodies in early HIV infection which enhances its utility in early HIV diagnosis.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-HIV-1 IgM antibody; Early detection; HIV gp41 antigen; INSTI; IgM removal; Protein A

Mesh:

Substances:

Year:  2015        PMID: 26311612     DOI: 10.1016/j.jcv.2015.08.005

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Field performance of the INSTI HIV-1/-2 antibody test in two South African antenatal clinics.

Authors:  Simnikiwe H Mayaphi; Desmond J Martin; Thomas C Quinn; Anton C Stoltz
Journal:  J Med Virol       Date:  2019-03-18       Impact factor: 2.327

2.  Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources.

Authors:  Simnikiwe H Mayaphi; Desmond J Martin; Thomas C Quinn; Oliver Laeyendecker; Steve A S Olorunju; Gregory R Tintinger; Anton C Stoltz
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

3.  Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test.

Authors:  Geraldine Guillon; Graham Yearwood; Casey Snipes; Daniel Boschi; Michael R Reed
Journal:  PeerJ       Date:  2018-02-28       Impact factor: 2.984

Review 4.  Recent advances in lab-on-a-chip technologies for viral diagnosis.

Authors:  Hanliang Zhu; Zdenka Fohlerová; Jan Pekárek; Evgenia Basova; Pavel Neužil
Journal:  Biosens Bioelectron       Date:  2020-01-22       Impact factor: 10.618

5.  Evaluation of HIV-1 rapid tests and identification of alternative testing algorithms for use in Uganda.

Authors:  Pontiano Kaleebu; Paul Kato Kitandwe; Tom Lutalo; Aminah Kigozi; Christine Watera; Mary Bridget Nanteza; Peter Hughes; Joshua Musinguzi; Alex Opio; Robert Downing; Edward Katongole Mbidde
Journal:  BMC Infect Dis       Date:  2018-02-27       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.